In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, William Kearney and Dan Gong, MD, discussed how patients with a unilateral retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.
DME showed small significant improvement in study cohort.
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Data were presented during an oral presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago.
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.
Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.
Recent reports of retinal atrophy have raised concerns on potential long-term safety.
The advanced swept-source OCT technology allows visualization of the variations in the normal changes and those associated with aging in the posterior vitreous.
Fluocinolone acetonide intravitreal implant or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy
Coherus BioSciences’ ranibizumab-eqrn is the first and only FDA-approved biosimilar interchangeable with ranibizumab injection for all indications, with 12 months of interchangeability exclusivity.
Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.
Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.
According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.
According to the company, the NDA submission for Nyxol eye drops in first indication is on track for late 2022.
Scientist have proposed several methods for converting stem cells into RPE, but there is still a gap in our knowledge of how cells respond to these stimuli over time.
During the 22nd European Society of Retina Specialists Congress in Hamburg, Germany., investigators noted that Yusar and colleagues from the Vitreoretinal Services, Centre for Sight, Delhi, India.
GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. With this data in hand, Iveric Bio is working to submit a New Drug Application for Zimura to the FDA by the end of the first quarter of next year.
According to a presentation by the company at the 22nd EURETINA World Congress in Hamburg, Germany, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
